SCHEMBL6505656

SCHEMBL6505656

COC(=O)c1ccc2nc(C)n(Cc3cc([N+](=O)[O-])c(Cl)cc3Cl)c2n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 2/20 0.42
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
AGTR1 P30556 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CFTR P13569 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
JAK2 O60674 1/20 0.35
RAB9A P51151 1/20 0.35
HKDC1 Q2TB90 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491706 0.89 KMT2A (0.41) DCTPP1MEN1KMT2AMAPTLMNA
SCHEMBL7837434 0.89 KMT2A (0.41) DCTPP1MEN1KMT2AMAPTLMNA
SCHEMBL6298849 0.86 KMT2A (0.46) DCTPP1MEN1KMT2AMAPTALDH1A1
SCHEMBL6299133 0.84 MAPT (0.38) DCTPP1MEN1KMT2AMAPTLMNA
SCHEMBL6504716 0.84 KDM4E (0.39) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL6491865 0.83 PTGS2 (0.43) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL6502254 0.82 MAPT (0.37) DCTPP1MEN1KMT2AMAPTLMNA
SCHEMBL6300374 0.82 PPARG (0.47) MAPTLMNAALDH1A1HTTNPSR1
SCHEMBL6305523 0.82 MAPT (0.41) DCTPP1MEN1KMT2AMAPTLMNA
SCHEMBL6299292 0.81 MAPT (0.41) DCTPP1MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A DCTPP1 2259/4885MEN1 2819/4885KMT2A 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.